NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon reported today an 8 percent decrease year over year in its second quarter revenues.

For the three months ended June 30, revenues totaled DKK 30.7 million ($5.5 million), down from DKK 33.3 million in the year-ago period. The firm said research product sales and services declined 3 percent year over year to DKK 24.9 million in the quarter, while service revenues fell 10 percent to DKK 3.7 million.

Exiqon did not break out the rest of its revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.